Cefiderocol (S-649266; GSK-2696266D; S-649266D; trade name Fetroja) is an injectable siderophore cephalosporin antibiotic that has a catechol moiety on the 3-position of the side chain and was under clinical trials by Shionogi. It exhibits potent in vitro activity against
the non-fermenting Gram- bacteria such as Acinetobacter baumannii,
Pseudomonas aeruginosa and Stenotrophomonas maltophilia. As of Nov 14, 2019, Cefiderocol has gained FDA approval to treat patients with complicated UTI-urinary tract infections who have no other options available. It is indicated for the treatment of multi-drug-resistant
Gram- bacteria such as Pseudomonas aeruginosa.